Related Experiment Video
Updated: May 28, 2025
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
Multiplex analysis of ovarian cancer patients using glycan microarray
Vadim S Pokrovsky1, Louay Abo Qoura1, Aleksei A Tikhonov2
1N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of Russian Federation, 115478, Moscow, Russia; Research Institute of Molecular and Cellular Medicine, People's Friendship University of Russia (RUDN University), 117198, Moscow, Russia.
Tumor-associated glycan antigens (TAGs) show promise as ovarian cancer biomarkers. Analysis of anti-glycan antibodies in patient serum revealed distinct profiles, suggesting potential for early cancer diagnostics.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Tumor-associated glycan antigens (TAGs) are crucial in cancer development.
- Glycan microarrays offer a powerful tool for analyzing TAGs and anti-glycan antibodies.
- TAGs are emerging as promising biomarkers for oncological diagnostics and therapeutics.
Purpose of the Study:
- To investigate changes in anti-glycan IgG and IgM antibody profiles in ovarian cancer (OvaCan) patients.
- To evaluate the diagnostic potential of specific anti-glycan antibodies using glycan microarrays.
- To identify novel serological biomarkers for ovarian cancer detection.
Main Methods:
- Serum samples from 203 ovarian cancer patients and healthy volunteers were analyzed.
- A glycan microarray with 63 immobilized glycans was employed.
- Levels of anti-glycan IgG and IgM antibodies were quantified and compared between groups.
Main Results:
- Statistically significant differences in anti-glycan IgG and IgM antibody levels were observed between OvaCan patients and healthy donors.
- 6-O-su-Lec showed a significant difference in IgG antibody levels (AUC=0.657).
- Ley demonstrated high specificity (Sp=98.0%) for IgM antibodies in diagnosing OvaCan (AUC=0.625).
Conclusions:
- Anti-glycan antibody profiles differ significantly between ovarian cancer patients and healthy individuals.
- Specific antibodies, such as anti-6-O-su-Lec IgG and anti-Ley IgM, show potential as ovarian cancer biomarkers.
- Further large-scale studies are required to validate these findings and explore their utility in diagnosing various cancer types.
